-
Understanding C-Peptide: A Key Biomarker Advancing Type 1 Diabetes Research
C-peptide, a byproduct of insulin production, is helping researchers better measure remaining beta-cell function in people with type 1 diabetes—supporting progress toward new therapies.
-
FDA Advisory Panel Recommends Easing Restrictions on Popular Peptides
An FDA advisory panel has voted to recommend loosening current restrictions on certain peptide compounds, a move that could expand access for patients and practitioners.
-
FDA Advisory Committee Backs Compounding for Six Popular Peptides
An FDA advisory panel has determined that six widely used peptides meet the criteria for pharmacy compounding, a step that could preserve patient access to these therapies through compounding pharmacies.
-
6 Popular Peptides May Soon Be Easier to Access, Report Suggests
A new report highlights that several popular peptides could soon become more accessible to consumers, reflecting growing mainstream interest in peptide therapies. Easier access could mean more people benefiting from these emerging treatments under proper guidance.
-
FDA Panel Vote Signals Potential for Easier Access to Popular Peptides
A recent FDA panel vote could pave the way for millions of Americans to gain easier access to popular peptide compounds, marking a potentially significant shift in regulatory approach.
-
GLP-1 Peptide Therapy Shows Promise in Reducing Heavy Drinking, Trial Finds
Altimmune’s GLP-1-based drug demonstrated a reduction in heavy drinking days among participants with alcohol use disorder in a recent clinical trial, opening a potential new avenue for treatment.
-
FDA Signals Broader Peptide Access—Minnesota Pharmacies Gear Up
Reports indicate the FDA may expand availability of certain peptides, prompting Minnesota compounding pharmacies to prepare for increased demand and patient access.
-
FDA Advisory Panel Recommends Easing Regulations for Certain Peptides
An FDA advisory panel has recommended loosening regulatory restrictions on select peptides, responding to growing public and scientific interest in this category of compounds.
-
FDA Peptide Review Could Expand Access Through Compounding Pharmacies
A new FDA review of peptide compounds may open the door for compounding pharmacies to prepare more peptide-based therapies, potentially widening patient access to these treatments.
-
FDA Advisory Committee Backs Continued Access to Compounded Peptides
An FDA advisory committee voted in favor of preserving access to certain compounded peptides, a notable win for patients and practitioners who rely on these therapies.